Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

ClinicalTrials.gov ID: NCT04631016

Public ClinicalTrials.gov record NCT04631016. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis (FRONTIER 4)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult participants with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.

Study identification

NCT ID
NCT04631016
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
137 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 13, 2020
Primary completion
May 29, 2023
Completion
Nov 12, 2023
Last update posted
Feb 26, 2025

2020 – 2023

United States locations

U.S. sites
16
U.S. states
13
U.S. cities
16
Facility City State ZIP Site status
Research Site Sheffield Alabama 35660
Research Site Newport Beach California 92663
Research Site Newark Delaware 19713
Research Site Kissimmee Florida 34746
Research Site Ormond Beach Florida 32174
Research Site Winter Park Florida 32789
Research Site Lakeside Park Kentucky 41017
Research Site White Marsh Maryland 21162
Research Site Ann Arbor Michigan 48197
Research Site New Bern North Carolina 28562
Research Site Columbus Ohio 43215
Research Site Oklahoma City Oklahoma 73120
Research Site Pittsburgh Pennsylvania 15213
Research Site North Charleston South Carolina 29406
Research Site Spartanburg South Carolina 29303
Research Site Boerne Texas 78006

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04631016, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 26, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04631016 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →